CMPS — COMPASS Pathways plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1816590 ·
Last close
$12.23
Market Cap
$1.65B
52W High
$12.48
52W Low
$4.88
ADV30
5,670,983
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -40,427,000 | 91,202,000 | 531,739,000 | 466,010,000 | 205,052,000 |
| Dec 2025 | 0 | — | -58,864,000 | -93,878,000 | 210,349,000 | 149,608,000 | 263,197,000 |
| Sep 2025 | 0 | — | -36,612,000 | -137,717,000 | 255,607,000 | 185,937,000 | 218,016,000 |
| Jun 2025 | 0 | — | -38,646,000 | -38,403,000 | 293,536,000 | 221,881,000 | 130,981,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-157,240,000
Investing CF
$0
Financing CF
$140,712,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.09
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-822,594,000
Inventory
—
Receivables
$15,387,000
ST Investments
—
EBIT TTM
$-285,818,000
Pretax Income TTM
$-290,335,000
Interest Exp TTM
$4,517,000
Analysts
14
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -175,290,000 | -287,862,000 | 210,349,000 | 263,197,000 | — | -157,240,000 |
| Dec 2024 | 0 | -157,108,000 | -155,122,000 | 213,666,000 | 58,971,000 | — | -119,186,000 |
| Dec 2023 | 0 | -124,044,000 | -118,464,000 | 275,987,000 | 50,243,000 | — | -97,376,000 |
| Dec 2022 | 0 | -95,979,000 | -91,505,000 | 197,294,000 | 16,014,000 | — | -105,451,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,977,000
NetIncome TTM
$-54,351,000
OpCashFlow TTM
$0
Assets (Latest)
$213,666,000
Forward EPS
$-1.06
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $11.00 · spot: $12.23 · call volume: 4,040 · put volume: 237
Expected Move to 2026-07-17:
±$3.60
(29.45%) —
implied range
$8.63 –
$15.83
· ATM straddle on $12.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NUVB | Nuvation Bio Inc. | $1.63B | $4.69 | — |
| INVA | Innoviva, Inc. | $1.67B | $22.68 | — |
| ANAB | ANAPTYSBIO, INC | $1.68B | $57.77 | — |
| ABCL | AbCellera Biologics Inc. | $1.62B | $5.29 | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.68B | $28.33 | — |
News headlines (Yahoo Finance, 1h cache)
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
2026-05-26 10:30 · Yahoo
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins
2026-05-21 06:03 · Yahoo
This Psychedelics Stock Just Keeps Getting Hotter; Why Shares Bypassed A Profit-Taking Zone
2026-05-18 20:07 · Yahoo
Assessing COMPASS Pathways (CMPS) Valuation After Strong Q1 2026 Earnings And Key FDA Milestones
2026-05-15 03:15 · Yahoo
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
2026-05-14 10:30 · Yahoo
Compass Pathways PLC (CMPS) Q1 2026 Earnings Call Highlights: Promising Advances in ...
2026-05-13 23:02 · Yahoo
Transcript: Compass Pathways Q1 2026 Earnings Conference Call
2026-05-13 22:34 · Yahoo
Here's Why This Psychedelics Stock Just Took A Trip To A Two-Year High
2026-05-13 20:08 · Yahoo
Compass (CMPS) Q1 2026 Earnings Transcript
2026-05-13 18:55 · Yahoo
Compass Pathways shares rise on Q1 results, accelerated FDA review
2026-05-13 16:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.